467 related articles for article (PubMed ID: 15003450)
21. Point mutation in the alpha-galactosidase A gene of atypical Fabry disease with only nephropathy.
Sawada K; Mizoguchi K; Hishida A; Kaneko E; Koide Y; Nishimura K; Kimura M
Clin Nephrol; 1996 May; 45(5):289-94. PubMed ID: 8738659
[TBL] [Abstract][Full Text] [Related]
22. Fabry disease: twenty novel alpha-galactosidase A mutations causing the classical phenotype.
Ashley GA; Shabbeer J; Yasuda M; Eng CM; Desnick RJ
J Hum Genet; 2001; 46(4):192-6. PubMed ID: 11322659
[TBL] [Abstract][Full Text] [Related]
23. Role of Ser-65 in the activity of alpha-galactosidase A: characterization of a point mutation (S65T) detected in a patient with Fabry disease.
Ishii S; Suzuki Y; Fan JQ
Arch Biochem Biophys; 2000 May; 377(2):228-33. PubMed ID: 10845698
[TBL] [Abstract][Full Text] [Related]
24. Novel human pathological mutations. Gene symbol: GLA. Disease: Fabry disease.
Chien YH
Hum Genet; 2009 Apr; 125(3):336. PubMed ID: 19309800
[No Abstract] [Full Text] [Related]
25. Mutation analysis of alpha-galactosidase a gene in Hungarian Fabry patients.
László A; Török L; Raffai S; Török E; Sallay E; Endreffy E; Morvai L; van Amstel JK
Ideggyogy Sz; 2012 Jan; 65(1-2):35-9. PubMed ID: 22338844
[TBL] [Abstract][Full Text] [Related]
26. Fabry disease in a female patient due to a de novo point mutation at position 691 of exon 5.
Brokalaki EI; Hentschke M; Grabbe S; Jansen T
Eur J Med Res; 2006 Jul; 11(7):306-8. PubMed ID: 16899426
[TBL] [Abstract][Full Text] [Related]
27. Enzymatic corrections for cells derived from Fabry disease patients by a recombinant adenovirus vector.
Ohsugi K; Kobayashi K; Itoh K; Sakuraba H; Sakuragawa N
J Hum Genet; 2000; 45(1):1-5. PubMed ID: 10697955
[TBL] [Abstract][Full Text] [Related]
28. Catalytic mechanism of human alpha-galactosidase.
Guce AI; Clark NE; Salgado EN; Ivanen DR; Kulminskaya AA; Brumer H; Garman SC
J Biol Chem; 2010 Feb; 285(6):3625-3632. PubMed ID: 19940122
[TBL] [Abstract][Full Text] [Related]
29. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin.
Ishii S; Chang HH; Kawasaki K; Yasuda K; Wu HL; Garman SC; Fan JQ
Biochem J; 2007 Sep; 406(2):285-95. PubMed ID: 17555407
[TBL] [Abstract][Full Text] [Related]
30. Purification and characterization of human alpha-galactosidase A expressed in insect cells using a baculovirus vector.
Chen Y; Jin M; Goodrich L; Smith G; Coppola G; Calhoun DH
Protein Expr Purif; 2000 Nov; 20(2):228-36. PubMed ID: 11049747
[TBL] [Abstract][Full Text] [Related]
31. Expression and characterization of glycosylated and catalytically active recombinant human alpha-galactosidase A produced in Pichia pastoris.
Chen Y; Jin M; Egborge T; Coppola G; Andre J; Calhoun DH
Protein Expr Purif; 2000 Dec; 20(3):472-84. PubMed ID: 11087687
[TBL] [Abstract][Full Text] [Related]
32. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
Takenaka T; Murray GJ; Qin G; Quirk JM; Ohshima T; Qasba P; Clark K; Kulkarni AB; Brady RO; Medin JA
Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7515-20. PubMed ID: 10840053
[TBL] [Abstract][Full Text] [Related]
33. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
34. A successful approach for the detection of Fabry patients in Argentina.
Rozenfeld PA; Tarabuso A; Ebner R; Ramallo G; Fossati CA
Clin Genet; 2006 Apr; 69(4):344-8. PubMed ID: 16630168
[TBL] [Abstract][Full Text] [Related]
35. [Mutation of the alpha-galactosidase A gene in two unusual variations of Fabray's disease].
Beĭer EM; Kopishinskaia SV; Ploos van Amstel JK; Tsvetkova IV
Vopr Med Khim; 1999; 45(4):346-9. PubMed ID: 10547886
[TBL] [Abstract][Full Text] [Related]
36. Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome.
Nance CS; Klein CJ; Banikazemi M; Dikman SH; Phelps RG; McArthur JC; Rodriguez M; Desnick RJ
Arch Neurol; 2006 Mar; 63(3):453-7. PubMed ID: 16533976
[TBL] [Abstract][Full Text] [Related]
37. Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease.
Schäfer E; Baron K; Widmer U; Deegan P; Neumann HP; Sunder-Plassmann G; Johansson JO; Whybra C; Ries M; Pastores GM; Mehta A; Beck M; Gal A
Hum Mutat; 2005 Apr; 25(4):412. PubMed ID: 15776423
[TBL] [Abstract][Full Text] [Related]
38. Five novel mutations in fourteen patients with Fabry Disease.
Rosenberg KM; Schiffmann R; Kaneski C; Brady RO; Sorensen SA; Hasholt L
Hum Mutat; 2000 Feb; 15(2):207-8. PubMed ID: 10649504
[TBL] [Abstract][Full Text] [Related]
39. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors.
Fan JQ; Ishii S
FEBS J; 2007 Oct; 274(19):4962-71. PubMed ID: 17894781
[TBL] [Abstract][Full Text] [Related]
40. Novel human pathological mutations. Gene symbol: GLA. Disease: Fabry disease.
Lin HY; Chong KW; Hsu JH; Yu HC; Huang CH; Niu DM
Hum Genet; 2010 Jan; 127(1):124. PubMed ID: 20108438
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
